BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Takeda Blood Cancer Drug Fails in Phase III

  Takeda said that Phase III PANTHER, which studied the effectiveness of pevonedistat for different types of leukemia, did not produce significant results in terms of event-free survival.

  September 2, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  BioSpace Movers & Shakers: Sept. 3

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

  September 2, 2021

   · 

  7 min read

   · 

  Alex Keown
• 

  Drug Development

  Pfizer Doubles Down on Respiratory Viruses with RSV and COVID Pill Trials

  Pfizer dosed its first patients in a Phase III trial assessing a single dose of its investigational RSV bivalent prefusion F subunit vaccine candidate (RSVpreF) in adults ages 60 and above.

  September 2, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  FDA Crackdown on JAK Drug Class Unwelcome News for Pharma Giants

  Henceforth, all JAK-inhibiting drugs like AbbVie’s Rinvoq, Pfizer’s Xeljanz, and Lilly’s Olumiant, have been ordered to include a warning label on the medicine to be sold in the U.S.

  September 2, 2021

   · 

  4 min read

   · 

  BioSpace Editorial Staff
• 

  Drug Development

  Vaccines Cut “Long-Haul” COVID Risk in Half, While Kids Test Positive in Droves

  A study published in The Lancet Infectious Diseases found that the Pfizer-BioNTech, Oxford-AstraZeneca or Moderna vaccines resulted in a drop in “long-haul” COVID-19 by 50%.

  September 2, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Deals

  Judge Releases Sacklers from Future Opioid Lawsuits, Approves Purdue Settlement

  The Sacklers did not admit to any wrongdoing and have never been charged directly for the issue. Still, Purdue Pharma has pleaded guilty twice in its erroneous marketing efforts for OxyContin.

  September 2, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Genetown

  Biogen Giving Out Free Doses of Alzheimer’s Drug Aduhelm

  The company sent the medication to a Florida neurology clinic free of charge.

  September 2, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Genetown

  Investors Hand Disc Medicine $90 Million to Control Hematological Diseases

  Disc’s first program, DISC-0974, is an anti-hemojuvelin (HJV) monoclonal antibody designed to suppress hepcidin and enhance iron levels in order to treat anemia of inflammation.

  September 2, 2021

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Career Advice

  3 Ways to Encourage Positive Mental Health at Work

  The pandemic and its subsequent effect on the workplace has been the source of stress for many professionals. Here are 3 ways to boost mental health at work.

  September 2, 2021

   · 

  4 min read

   · 

  Porschia Parker-Griffin
• 

  BioMidwest

  Research Roundup: COVID-19 Antibody Responses and More

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

  September 2, 2021

   · 

  6 min read

   · 

  Mark Terry